Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study.

Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, Liebler EJ, Rubenstein Engel E, Tepper SJ; ACT1 Study Group..

Headache. 2016 Sep;56(8):1317-32. doi: 10.1111/head.12896.

PMID:
27593728
2.

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.

Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR; EVENT Study Group..

Neurology. 2016 Aug 2;87(5):529-38. doi: 10.1212/WNL.0000000000002918.

3.

Are Chronic and Episodic Migraine Distinct Neurophysiological Entities? More Research is Needed.

Saper JR.

Pain Med. 2015 Jul;16(7):1246. doi: 10.1111/pme.12805. No abstract available.

4.

Medication overuse headache: history, features, prevention and management strategies.

Saper JR, Da Silva AN.

CNS Drugs. 2013 Nov;27(11):867-77. doi: 10.1007/s40263-013-0081-y. Review.

PMID:
23925669
5.

Oral methylergonovine maleate for refractory migraine and cluster headache prevention.

Saper JR, Evans RW.

Headache. 2013 Feb;53(2):378-81. doi: 10.1111/head.12033. Review. No abstract available.

PMID:
23432443
6.

Migraine headache is present in the aura phase: a prospective study.

Hansen JM, Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Goadsby PJ, Charles A.

Neurology. 2012 Nov 13;79(20):2044-9. doi: 10.1212/WNL.0b013e3182749eed.

7.

Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.

Ho TW, Pearlman E, Lewis D, Hämäläinen M, Connor K, Michelson D, Zhang Y, Assaid C, Mozley LH, Strickler N, Bachman R, Mahoney E, Lines C, Hewitt DJ; Rizatriptan Protocol 082 Pediatric Migraine Study Group..

Cephalalgia. 2012 Jul;32(10):750-65.

PMID:
22711898
8.

Randomized, controlled trial of telcagepant over four migraine attacks.

Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, Lines CR, Ho TW.

Cephalalgia. 2010 Dec;30(12):1443-57. doi: 10.1177/0333102410370878.

PMID:
20974601
9.

Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT).

Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino JV, Quiring JN, Saper JR.

Cephalalgia. 2010 Nov;30(11):1336-45. doi: 10.1177/0333102410367523.

PMID:
20959428
10.

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study.

Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ; ONSTIM Investigators..

Cephalalgia. 2011 Feb;31(3):271-85. doi: 10.1177/0333102410381142.

11.

A practice guide for continuous opioid therapy for refractory daily headache: patient selection, physician requirements, and treatment monitoring.

Saper JR, Lake AE 3rd, Bain PA, Stillman MJ, Rothrock JF, Mathew NT, Hamel RL, Moriarty M, Tietjen GE.

Headache. 2010 Jul;50(7):1175-93. doi: 10.1111/j.1526-4610.2010.01733.x. Review.

PMID:
20649650
12.

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.

Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group..

Cephalalgia. 2010 Jul;30(7):804-14. doi: 10.1177/0333102410364677.

13.

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group..

Cephalalgia. 2010 Jul;30(7):793-803. doi: 10.1177/0333102410364676.

14.

Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial.

Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, Fischell RE, Ruppel PL, Goadsby PJ.

Lancet Neurol. 2010 Apr;9(4):373-80. doi: 10.1016/S1474-4422(10)70054-5.

PMID:
20206581
15.

Comprehensive inpatient treatment of refractory chronic daily headache.

Lake AE 3rd, Saper JR, Hamel RL.

Headache. 2009 Apr;49(4):555-62. doi: 10.1111/j.1526-4610.2009.01364.x.

PMID:
19245391
16.

Continuous opioid therapy (COT) is rarely advisable for refractory chronic daily headache: limited efficacy, risks, and proposed guidelines.

Saper JR, Lake AE 3rd.

Headache. 2008 Jun;48(6):838-49. doi: 10.1111/j.1526-4610.2008.01153.x. Review.

PMID:
18549361
17.

Pearls from an inpatient headache unit.

Saper JR.

Headache. 2008 Jun;48(6):820-7. doi: 10.1111/j.1526-4610.2008.01141.x. Review.

PMID:
18549359
18.

Fifty years of headache care evolution: from a few interested doctors to certified specialists and comprehensive systems.

Saper JR.

Headache. 2008 May;48(5):701-3. doi: 10.1111/j.1526-4610.2008.01100.x.

PMID:
18471115
19.

Chronic daily headache: transformational migraine, chronic migraine, and related disorders.

Saper JR.

Curr Neurol Neurosci Rep. 2008 Mar;8(2):100-7. Review.

PMID:
18460277
20.

A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.

Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM; BoNTA-009 Study Group..

Pain Med. 2007 Sep;8(6):478-85.

Items per page

Supplemental Content

Loading ...
Support Center